KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Non-Current Liabilities (2019 - 2025)

Royalty Pharma's Total Non-Current Liabilities history spans 7 years, with the latest figure at $9.3 billion for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 18.37% year-over-year to $9.3 billion; the TTM value through Dec 2025 reached $9.3 billion, up 18.37%, while the annual FY2025 figure was $9.3 billion, 18.37% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $9.3 billion at Royalty Pharma, down from $9.6 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $9.6 billion in Q3 2025 and bottomed at $6.3 billion in Q3 2023.
  • The 5-year median for Total Non-Current Liabilities is $7.3 billion (2022), against an average of $7.6 billion.
  • The largest annual shift saw Total Non-Current Liabilities dropped 13.62% in 2023 before it grew 25.15% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $7.3 billion in 2021, then rose by 0.25% to $7.3 billion in 2022, then fell by 13.57% to $6.3 billion in 2023, then grew by 25.15% to $7.9 billion in 2024, then grew by 18.37% to $9.3 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Total Non-Current Liabilities are $9.3 billion (Q4 2025), $9.6 billion (Q3 2025), and $8.7 billion (Q2 2025).